



Disclaimer

The information contained in this document ("Presentation") has been prepared by Totally plc (the "Company") The Company is a UK company quoted on AIM, a market operated by London Stock Exchange plc. This Presentation has not been verified nor has it been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA") and therefore it is being provided for information purposes only.

Allenby Capital Limited ("Allenby Capital"), which is authorised and regulated by the Financial Conduct Authority, is acting as the nominated adviser and joint broker to the Company. Canaccord Genuity Limited ("Canaccord"), which is authorised and regulated by the Financial Conduct Authority, is acting as joint broker to the Company. Accordingly, the recipients should note that Allenby Capital and Canaccord are neither advising nor treating as a client any other person and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Allenby Capital and Canaccord nor for providing advice in relation to the matters contained in this Presentation.

While the information contained herein has been prepared in good faith, neither the Company nor any of its directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

The views of the Company's management/directors and/or its partners set out in this document could ultimately prove to be incorrect. No warranty, express or implied, is given by the presentation of these figures here and investors should place no reliance on the Company's estimates cited in this document.

This Presentation may contain "forward-looking statements" that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, performance, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on

circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

This Presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute or form part of any offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in these slides or the Presentation or on the completeness, accuracy or fairness thereof. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

Neither this Presentation nor any copy of it may be (a) taken or transmitted into Australia, Canada, Japan, the Republic of South Africa or the United States of America (each a "Restricted Territory"), their territories or possessions; (b) distributed to any U.S. person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)) or (c) distributed to any individual outside a Restricted Territory who is a resident thereof in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

Agenda

FY 2022 preliminary results

- Business overview, Wendy Lawrence, CEO
- Financial highlights, Lisa Barter, CFO
- Strategic update, Wendy Lawrence, CEO



Another record year

Record revenue and profit

Two strategic acquisitions completed

Delivered services to 2.5 million patients

Our trading divisions and businesses

Completed two acquisitions during the year enabling the provision of an expanded range of services which support the improvement of healthcare outcomes both directly (through services delivered on behalf of the NHS) and indirectly (by increasing focus on physical and mental wellbeing through corporate employers).



- Made up of Vocare and Greenbrook Healthcare.
- Provides urgent care services including urgent treatment centres, NHS 111 and GP Out of Hours.



- Made up of Premier Physical
 Healthcare, Optimum Physiotherapy
 and About Health.
- Provides physiotherapy and outpatient services to NHS such as First Contact Practitioner and community dermatology clinics.
- Provider of physiotherapy and occupational therapy for prison services.



- Acquired in March 2022.
- Provider of insourcing and outsourcing services including difficult to acquire 'Any Qualified provider' status.
- Now incorporates Totally Healthcare, Totally's existing insourcing provider.



- Acquired in December 2021.
- Provides a range of corporate fitness, wellbeing and occupational health services to help corporate customers improve the health and wellbeing of their workforce.

Our services

Completed two acquisitions during the year enabling the provision of an expanded range of services which support the improvement of healthcare outcomes both directly (through services delivered on behalf of the NHS) and indirectly (by increasing focus on physical and mental wellbeing through corporate employers).



Urgent care

 Delivers urgent care services including urgent treatment centres, NHS 111 and GPOOH on behalf of NHS; ensuring patents have access to the right healthcare service, at the right time, both in and out of hours.



Elective care and outpatient services

 Supports NHS with reduction of waiting lists through insourcing, outsourcing and outpatient services such as community dermatology clinics.



First Contact Practitioner

physiotherapists into GP practices to deliver appointments meaning that patients with MSK conditions bypass the GP, freeing up appointments and making wait and recovery times shorter.



Prison health

 Working within prison services to offer complete physiotherapy and occupational therapy services.



Corporate wellbeing

 Provide a range of corporate fitness, wellbeing and occupational health services to help corporate customers improve the health and wellbeing of their workforce

Helping to reduce waiting times across the NHS

Delivered services to 2.5 million patients during the year.

- 1.4 million + patients assessed by NHS111 and CAS.
- 800,000+ patients treated in urgent treatment centres.
- 180,000 patients supported out of hours.
- c. 30,000 physiotherapy patients.
- c. 55,000 community dermatology appointments.
- c. 28,000 insourcing patients.
- 11,500 gym members.



Financial highlights Lisa Barter, CFO

Performance above expectation

Strong performance in all areas, delivering:

- £1.3 million PBT (2021:£0.1 million).
- Increased Earnings Per Share.
- c. £10 million revenue from insourcing services.
- Completed two very strategic acquisitions.
- Urgent Care Division gross margin maintained at 17.8%.
- Reduction in administrative costs as a percentage of revenue.



Outstanding trading performance

Further sustainable growth delivered through a combination of organic growth and sensible M&A activity.


- Revenue up 12% YoY at £127.4 million.
- Underlying EBITDA increased 24% to £6.2 million.
- Profit before tax £1.3 million (FY21: £0.1 million).
- Gross margin at 18.0% (FY21: 18.3%) margin pressure on specific non-urgent care contracts.

Positive cash generation


- £15.3 million cash at bank (31 March 2021: £14.8 million).
- £5 million RCF in place.
- No debt.













Record revenue across all trading divisions and businesses



- Organic growth of 11% was driven by the increase in Insourcing revenues, up £6.5 million.
 - Urgent Care up 3.6% to £109.2 million.
 - Planned Care revenue up by £2.3 million as the number of face to face consultations normalised.
 - Totally Healthcare revenue tripled to £9.6 million as activity to reduce waiting lists for elective care was initiated.
- M&A activity contributed £1 million revenue in FY22.
 - Additional £0.7 million was contributed by Pioneer Health Care for period from 10 March 2022.
 - EFP revenue for period from 16 December 2021 totalled £0.3 million.
- 2022 revenue through acquisition exit run rate £12.8 million p.a.


Strong position on core metrics

Margin **18.0%**




- Group Gross Margin 18.0% (2021: 18.3%).
- Urgent Care Gross Margin maintained at 17.8% (2021:17.8%).
- Rest of business Gross Margin at 19.0% (2021:25.0%).

Underlying EBITDA **£6.2m** +24%



- EBITDA of £6.2 million before exceptional items of £0.2 million relating to the acquisition costs of EFP and Pioneer Health Care.
- Substantial increase in profit before tax to £1.3 million (FY21: £0.1 million).

Cash **£15.3m** +3.4%



 Strong cash generation - £7.4 million utilised to complete two acquisitions during the period.

Strategic update Wendy Lawrence, CEO

Significant progress against strategic objectives

Core market growth



- Acquisition of Pioneer Health Care in March 2022.
- Successfully mobilised new contracts in Staffordshire and London.
- Continued delivery of COVID-19 specific services.
- Developed new models of care such as virtual streaming.

Market share growth



- Continued to deliver services during further year impacted by COVID-19 pandemic.
- New contract wins and multiple contract extensions to provide consistency of service, whilst underpinning recurring revenues.

Driving benefit through identification of synergies



- Implementation of new HR and finance system.
- Alignment of all company branding.
- Launch of Group-wide intranet, new websites and a new fully integrated email system.
- Integration of Pioneer into Totally Group and Totally Healthcare into Pioneer.

Building strong longterm relationships



- All registered services continue to be rated 'Good' by CQC.
- Multiple contract extensions to provide consistency of service, whilst underpinning recurring revenues.

Buy and Build



- Acquisition of Pioneer Health Care to expand capability to deliver insourcing and outsourcing services.
- Acquisition of Energy
 Fitness Professionals to expand into corporate wellbeing market.

Market continues to present significant opportunity despite ongoing COVID-19 challenges

Opportunities

- **Urgent care:** Growing and ageing population, alongside challenges accessing primary care, resulting in continued strong demand for urgent care services.
- **Elective care:** Waiting lists for elective care presenting challenges prior to COVID-19 now stand at highest levels to date.
- Corporate wellbeing: Corporate employers
 increasingly seeking to support their employees with
 health and wellbeing, ultimately reducing pressure on
 healthcare system.

Challenges

- COVID-19 pandemic continues to shape healthcare delivery:
 - Continued uncertainties: continuing to monitor case numbers to avoid impact on service delivery.
 - Increased demand: continued pressure on service as primary and secondary care struggle to respond.
 - Recruitment challenges: demand outstripping supply of medical and clinical staff as society returns to business as usual.
- Increased cost pressures including wage inflation and increased energy costs.

Focus for future growth is clear

Core market growth

- Contribute and influence NHS England strategy for the future of healthcare.
- Respond to new and emerging demand through the development of new models of care.
- Remain proactive with buy and build strategy.

Market share growth

- Contribute and influence NHS England strategy for the future of healthcare.
- Remain proactive with buy and build strategy.
- Expand current service models.
- Respond to new and emerging demand through the development of new models of care.

Driving benefit through identification of synergies

 Cross-selling of services across all customers.

Building strong longterm relationships

- Secure new contracts and further contract extensions with healthcare commissioners.
- Expand footprint across UK and Ireland.
- Develop new service model to address rising demand for services.

Buy and Build

- Maximise potential in the elective care market by driving growth through Pioneer and Planned Care.
- Develop digital technologies to accelerate growth and improve services.
- Seek out new earnings enhancing opportunities.

Conclusion

Record revenue and profit, strengthened for the future

- **Record results:** Revenue up 12% to £127 million; EBITDA up 24% to £6.2 million.
- **Strengthened for the future:** Two acquisitions completed and being integrated into business to support future growth.
- Significant market opportunities:
 - Continuing increases in demand for urgent care services.
 - record number of patients waiting to be treated.
 - renewed focus on corporate wellbeing.
- **Buy and build strategy remains in place:** continue to seek out sensible, earnings enhancing opportunities.



Totally

Cardinal Square West 10 Nottingham Road Derby, DE1 3QT

